Overview

* Vir Biotechnology ( VIR ) Q3 revenue missed analyst expectations, declining significantly year-over-year

* Net loss for Q3 decreased to $163.1 mln from $213.7 mln year-over-year

* Company maintains strong cash position with $810.7 mln, funding operations into mid-2027

Outlook

* Company expects cash reserves to fund operations into mid-2027

* Topline data for ECLIPSE trials expected in Q1 2027

Result Drivers

* R&D expenses for the third quarter of 2025 were $151.5 million,

* ONCOLOGY EXPANSION - First patient dosed in Phase 1 study of VIR-5500 in combination with ARPIs for prostate cancer

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $200,000 $1.98

Revenue mln (7

Analysts

)

Q3 EPS -$1.17

Q3 Net -$163.10

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Vir Biotechnology Inc ( VIR ) is $15.00, about 65% above its November 4 closing price of $5.25

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)